{"id":"NCT00797511","sponsor":"Sanofi","briefTitle":"Immunogenicity and Safety of Adacel Polio Vaccine","officialTitle":"Immunogenicity and Safety of ADACEL POLIO (TdcP-IPV Vaccine) Administered at 6 to 8 Years of Age as a Fifth Dose in Healthy Children in Taiwan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2009-04","completion":"2009-07","firstPosted":"2008-11-25","resultsPosted":"2012-11-26","lastUpdate":"2012-11-26"},"enrollment":132,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"TdcP-IPV vaccine","otherNames":["ADACEL POLIO"]}],"arms":[{"label":"Study Group","type":"EXPERIMENTAL"}],"summary":"The present study is designed to meet the requirements of the Taiwanese Health Authorities for registration of ADACEL POLIO in Taiwan.\n\nSubjects will receive one dose of the study vaccine at 6 to 8 years of age. Blood samples will be taken for antibody titration. The expected total duration of follow-up for each subject will be 28 days.","primaryOutcome":{"measure":"Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine.","timeFrame":"Day 28 post-vaccination","effectByArm":[{"arm":"ADACEL POLIO Vaccine Study Group","deltaMin":131,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":1,"countries":["Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":132},"commonTop":["Injection Site Pain","Injection site Erythema","Myalgia","Injection Site Swelling","Headache"]}}